Seneca Biopharma Financials

Seneca Biopharma Stock Summary

Seneca Biopharma competes with Alliant Energy, Aris Water, Barings BDC, BCB Bancorp, and PGE Corp. Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland. Neuralstem operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 5 people.

Seneca Biopharma Key Financial Ratios

Generally speaking, Seneca Biopharma's financial ratios allow both analysts and investors to convert raw data from Seneca Biopharma's financial statements into concise, actionable information that can be used to evaluate the performance of Seneca Biopharma over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Seneca Biopharma reports annually and quarterly.

Seneca Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Seneca Biopharma's current stock value. Our valuation model uses many indicators to compare Seneca Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Seneca Biopharma competition to find correlations between indicators driving Seneca Biopharma's intrinsic value. More Info.Seneca Biopharma is number one stock in return on equity category among related companies. It is number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Seneca Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Seneca Biopharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Seneca Biopharma's earnings, one of the primary drivers of an investment's value.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

If you are still planning to invest in Seneca Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seneca Biopharma's history and understand the potential risks before investing.